Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARD | Q03181 | 2/20 | 0.45 |
| ▸ | LPAR3 | Q9UBY5 | 10/20 | 0.43 |
| ▸ | LPAR2 | Q9HBW0 | 8/20 | 0.43 |
| ▸ | LPAR1 | Q92633 | 4/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | SAT1 | P21673 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18686723 | 0.88 | LPAR3 (0.54) | PPARDLPAR3LPAR2LPAR1CYP3A4 | |
| SCHEMBL27487331 | 0.86 | — | — | |
| SCHEMBL2486762 | 0.84 | CYP3A4 (0.58) | LPAR3LPAR2LPAR1CYP3A4 | |
| SCHEMBL28534817 | 0.84 | PPARD (0.41) | PPARDLPAR3LPAR2LPAR1CYP3A4 | |
| SCHEMBL18686721 | 0.83 | PPARD (0.42) | PPARDLPAR3LPAR2LPAR1CYP3A4 | |
| SCHEMBL9999835 | 0.82 | LPAR3 (0.43) | PPARDLPAR3LPAR2LPAR1CYP3A4 | |
| SCHEMBL17626529 | 0.82 | CYP3A4 (0.56) | LPAR3LPAR2LPAR1CYP3A4 | |
| SCHEMBL17626575 | 0.82 | CYP3A4 (0.56) | LPAR3LPAR2LPAR1CYP3A4 | |
| SCHEMBL777674 | 0.82 | LPAR3 (0.65) | LPAR3LPAR2LPAR1CYP3A4 | |
| SCHEMBL17626420 | 0.82 | CYP3A4 (0.56) | LPAR3LPAR2LPAR1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120142011-A1 | Modified siNA | QIAGEN GMBH | 2012-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120142011-A1 | Modified siNA | NSUN2, SIN3A, SNRPA1 | PPARD 4848/4885LPAR3 2147/4885LPAR2 2422/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.